New Webcast Interview With President and CEO Gerald Commissiong Now Available at

Sunnyvale, California, UNITED STATES

SUNNYVALE, Calif., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing MANF, a first-in-class disease–modifying therapeutic protein, announces today that its President and CEO Gerald Commissiong has conducted an exclusive new audio-taped webcast interview so that AMBS shareholders and the investment community can learn more about the Company's recent developments and growth plans. Unrestricted access to the webcast is now available on the "Webcasts" page at Investors who wish to receive The Green Baron Report for free can join at

The Green Baron Report also released a new report on AMBS yesterday after the close of trading to its members by email and posted the 17-page report on its website. The report states, "MANF represents a potential treatment for a range of diseases including Parkinson's, and the Company last month received its Notice of Allowance from the United States Patent & Trademark Office." It goes on to say, "Due to the fact that there is currently no cure for Parkinson's, any treatment demonstrating efficacy and safety could get fast tracked through the FDA testing and clearance process."  

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit">

About The Green Baron Report

The Green Baron Report is a subsidiary of Evergreen Marketing. The Green Baron Report is an internet stock market newsletter that focuses on low priced stocks that appear to have significant upside potential. For more information about Evergreen Marketing, Inc. and their subsidiary The Green Baron Investors Society visit them on the web at and or Our disclaimer can be viewed at

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

This information was brought to you by Cision,c9192144